The June 1, 2017, article by Martinelli et al entitled “Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study” (J Clin Oncol 35:1795-1802, 2017) contained an error.
On page 2, top of column 2 in the Patients and Methods section, the unit of measurement in the first sentence under “Study Procedures” was given incorrectly as:
“Patients received blinatumomab as a continuous intravenous infusion at fixed stepwise doses (9 µg/day in week 1 of cycle 1 followed by 28 mg/day thereafter).”
The sentence should read as:
“Patients received blinatumomab as a continuous intravenous infusion at fixed stepwise doses (9 µg/day in week 1 of cycle 1 followed by 28 µg/day thereafter).”
The online version has been corrected in departure from the print. JCO apologizes for the error.